Success Metrics

Clinical Success Rate
72.7%

Based on 8 completed trials

Completion Rate
73%(8/11)
Active Trials
0(0%)
Results Posted
113%(9 trials)
Terminated
3(25%)

Phase Distribution

Ph phase_2
4
33%
Ph phase_1
2
17%
Ph phase_3
6
50%

Phase Distribution

2

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
6(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

8 of 12 finished

Non-Completion Rate

33.3%

4 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(4)

Detailed Status

Completed8
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
72.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (16.7%)
Phase 24 (33.3%)
Phase 36 (50.0%)

Trials by Status

completed867%
terminated325%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_1

A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

NCT07464535
terminatedphase_3

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

NCT03841773
terminatedphase_3

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

NCT03110575
completedphase_2

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

NCT02421679
completedphase_2

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05472090
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07464535Phase 1

A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

Completed
NCT03841773Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Terminated
NCT03110575Phase 3

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Terminated
NCT02421679Phase 2

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Completed
NCT05472090Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Completed
NCT02277704Phase 2

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Completed
NCT03062540Phase 3

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

Terminated
NCT04508621Phase 3

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Completed
NCT05372887Phase 2

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

Withdrawn
NCT04172831Phase 3

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Completed
NCT04164719Phase 1

Dose-Proportionality and Food Effect Study of TNX-102 SL

Completed
NCT02015234Phase 3

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12